Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891769 · ClinicalTrials.gov registry record · Phase 2
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
A Phase 2 study of Parathyroid Adenoma, sponsored by Andrei Iagaru.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05891769 is a Phase 2 study of Parathyroid Adenoma that is actively recruiting participants, run by Andrei Iagaru. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05891769, a Phase 2 study of Parathyroid Adenoma, is actively recruiting participants, sponsored by Andrei Iagaru.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Conditions Studied
Interventions
- DRUG 18Fluorocholine
Study Locations (1)
California
- Stanford Hospital and Clinics - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891769
The ClinicalTrials.gov registry entry for NCT05891769 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parathyroid Adenoma appearing as the primary indexed condition, and to 1 intervention - of which 18Fluorocholine is the first listed.
NCT05891769 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05891769 about?
NCT05891769 is a clinical study titled "99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT". This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
What is the current status of trial NCT05891769?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-09-27. Estimated completion is 2027-07-01.
What conditions does trial NCT05891769 study?
This clinical trial studies the following conditions: Parathyroid Adenoma.
What interventions are being tested in trial NCT05891769?
The interventions under investigation include: 18Fluorocholine (DRUG).
Who is sponsoring clinical trial NCT05891769?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05891769 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.